2023-2024 Request for Proposals
The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, and treatment.
This cycle, proposals will be accepted for Team Science Awards, Academic-Industry Partnership Award (for Team Science Awards), Young Investigator Awards, Pilot Awards, and Dermatology Career Development Awards.
MRA plans to support at least $11.5 million in new funding in the 2023-2024 cycle.
Special Opportunities Included in RFP:
- Acral Melanoma Team Science, Young Investigator, & Pilot Awards focused on Advancing Translational Research for Acral Melanoma
- Brain Metastasis Team Science Award focused on Melanoma Brain Metastases Research co-funded by the Tara Miller Melanoma Foundation
- Dermatology Technologies Team Science Award focused on Novel Dermatology Technologies for Early Detection & Diagnosis
- Immunotherapy Young Investigator Awards supported by Bristol Myers Squibb (BMS)
- Radiation Oncology Young Investigator Award co-funded with the American Society for Radiation Oncology (ASTRO)
- Uveal Melanoma Pilot Award co-funded with A Cure in Sight (ACIS)
- UK or Israel-Based Young Investigator Award
Please Note the Following Key Deadlines:
- September 20, 2023: Letters of Intent (LOI) for Team Science Awards due
- October 20, 2023: Eligibility Checklist for Young Investigator & Dermatology Career Development Award applicants due
- November 3, 2023: Proposals for individual investigator awards due
- January 4, 2024: Invited Team Science Award full proposals due
- April 2024: Awardees notified of funding decisions
- June 1, 2024: Project Start Date
All proposals are due by 11:59 pm Eastern Time. Proposals should be submitted via the proposalCENTRAL online application tool: https://proposalcentral.com/
MRA accepts proposals from researchers worldwide and encourages applications from a diverse pool of investigators with respect to race, gender, sexual orientation, ethnicity, national origin, country of residence, and disability. MRA recognizes that diversity in the biomedical research workforce is critical for ensuring that the most creative minds have the opportunity to contribute to realizing our research goals and to ensuring more equitable health outcomes for all.
Rachel Fischer - Associate Director, Scientific Program & Registry: firstname.lastname@example.org